Enterobiotix

Edinburgh, United Kingdom Founded: 2017 • Age: 9 yrs
Microbiome-based therapeutics for gut diseases are developed.

About Enterobiotix

Enterobiotix is a company based in Edinburgh (United Kingdom) founded in 2017.. Enterobiotix has raised $72.96 million across 10 funding rounds from investors including Syndicate Room, Scottish Enterprise and NCIMB. The company has 65 employees as of December 31, 2023. Enterobiotix offers products and services including EBX-102-02 and IMT Therapies. Enterobiotix operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others.

  • Headquarter Edinburgh, United Kingdom
  • Employees 65 as on 31 Dec, 2023
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Enterobiotix Limited
  • Date of Incorporation 02 Mar, 2017
  • Jurisdiction GLASGOW, SCOTLAND
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $72.96 M (USD)

    in 10 rounds

  • Latest Funding Round
  • Investors
  • Employee Count
    65

    as on Dec 31, 2023

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Enterobiotix

Enterobiotix offers a comprehensive portfolio of products and services, including EBX-102-02 and IMT Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treatment for irritable bowel syndrome via gut restoration

Therapies to restore and enhance gut microbial ecology

People of Enterobiotix
Headcount 10-50
Employee Profiles 14
Board Members and Advisors 5
Employee Profiles
People
Tomasz Gąsior
Production Technologist
People
James McIlroy
CEO
People
Leo James
CMO
People
Lynsey Howard
Head of Research

Unlock access to complete

Board Members and Advisors
people
Mark R. Bamforth
Director
people
Iain Baird
Director
people
Douglas Thomson
Non Executive Director
people
David Lawrence
Director

Unlock access to complete

Funding Insights of Enterobiotix

Enterobiotix has successfully raised a total of $72.96M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 10
  • Last Round
  • First Round

    (21 Jun 2017)

  • Investors Count 12
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2026 Amount Series B - Enterobiotix Valuation

investors

Thairm Bio , The Scottish National Investment Bank
Mar, 2026 Amount Series B - Enterobiotix Valuation

investors

Jul, 2025 Amount Series B - Enterobiotix Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Enterobiotix

Enterobiotix has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Syndicate Room, Scottish Enterprise and NCIMB. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital fund focused on social impact companies
Founded Year Domain Location
Angel investment funding is facilitated for early-stage Scottish businesses.
Founded Year Domain Location
Early-stage investment is provided to promising Scottish entrepreneurs.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Enterobiotix

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Enterobiotix

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Enterobiotix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Enterobiotix

Enterobiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
domain founded_year HQ Location
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
domain founded_year HQ Location
Microbial therapeutics for skin diseases are developed.
domain founded_year HQ Location
Therapeutics for gastrointestinal diseases are developed and provided.
domain founded_year HQ Location
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Enterobiotix

Frequently Asked Questions about Enterobiotix

When was Enterobiotix founded?

Enterobiotix was founded in 2017.

Where is Enterobiotix located?

Enterobiotix is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.

Is Enterobiotix a funded company?

Enterobiotix is a funded company, having raised a total of $72.96M across 10 funding rounds to date. The company's 1st funding round was a Series B of $1.39M, raised on Jun 21, 2017.

How many employees does Enterobiotix have?

As of Dec 31, 2023, the latest employee count at Enterobiotix is 65.

What does Enterobiotix do?

Enterobiotix was founded in 2017 in Edinburgh, United Kingdom, within the biotechnology sector. Focus is placed on microbiome-based therapeutics targeting multiple diseases, especially those affecting the gut like Inflammatory Bowel Disease. An integrated anaerobic system is under development, featuring a closed benchtop setup for collection and processing that supports therapy production in anaerobic conditions without cleanrooms. Operations aim to deliver these treatments to patients through controlled, non-sterile environments.

Who are the top competitors of Enterobiotix?

Enterobiotix's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

What products or services does Enterobiotix offer?

Enterobiotix offers EBX-102-02 and IMT Therapies.

Who are Enterobiotix's investors?

Enterobiotix has 12 investors. Key investors include Syndicate Room, Scottish Enterprise, NCIMB, University of Aberdeen, and Kineticos.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available